CA3204120A1 - Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome - Google Patents

Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Info

Publication number
CA3204120A1
CA3204120A1 CA3204120A CA3204120A CA3204120A1 CA 3204120 A1 CA3204120 A1 CA 3204120A1 CA 3204120 A CA3204120 A CA 3204120A CA 3204120 A CA3204120 A CA 3204120A CA 3204120 A1 CA3204120 A1 CA 3204120A1
Authority
CA
Canada
Prior art keywords
mds
tasquinimod
pharmaceutically acceptable
acceptable salt
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3204120A
Other languages
English (en)
French (fr)
Inventor
Manja WOBUS
Katja SOCKEL
Martin Bornhauser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of CA3204120A1 publication Critical patent/CA3204120A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3204120A 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome Pending CA3204120A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21152018 2021-01-18
EP21152018.4 2021-01-18
EP21201509.3 2021-10-07
EP21201509 2021-10-07
EP21205665 2021-10-29
EP21205665.9 2021-10-29
PCT/EP2022/050891 WO2022152902A1 (en) 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
CA3204120A1 true CA3204120A1 (en) 2022-07-21

Family

ID=80034981

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3204120A Pending CA3204120A1 (en) 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Country Status (12)

Country Link
US (1) US20240091215A1 (enExample)
EP (1) EP4277628B1 (enExample)
JP (1) JP7837338B2 (enExample)
KR (1) KR20230133317A (enExample)
AU (1) AU2022208424A1 (enExample)
CA (1) CA3204120A1 (enExample)
ES (1) ES3057099T3 (enExample)
IL (1) IL304232A (enExample)
MX (1) MX2023008016A (enExample)
PL (1) PL4277628T3 (enExample)
WO (1) WO2022152902A1 (enExample)
ZA (1) ZA202307855B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240012436A (ko) 2021-05-25 2024-01-29 액티브 바이오테크 에이비 복수의 타스퀴니모드 입자 및 그 용도
WO2024137713A1 (en) * 2022-12-20 2024-06-27 Constellation Pharmaceuticals, Inc. Methods for treating lower risk myelodysplastic syndrome
CN122272585A (zh) * 2026-05-08 2026-06-26 吉林大学 他喹莫德在制备用于调控淋巴管炎症反应的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
WO2012004338A1 (en) 2010-07-09 2012-01-12 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
SI3016512T1 (sl) 2013-07-05 2020-07-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Topni CD33 za zdravljenje mielodisplastičnih sindromov (MDS)
SG11201607083VA (en) 2014-02-28 2016-09-29 Incyte Corp Jak1 inhibitors for the treatment of myelodysplastic syndromes
EP3041472B1 (en) * 2014-09-23 2017-02-01 Active Biotech AB Quinoline carboxamides for use in the treatment of multiple myeloma
BR112017009854B1 (pt) 2014-11-19 2022-08-23 Active Biotech Ab Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
JP2019127473A (ja) 2018-01-26 2019-08-01 学校法人同志社 多発性硬化症の治療及び／又は予防のための薬剤

Also Published As

Publication number Publication date
US20240091215A1 (en) 2024-03-21
ES3057099T3 (en) 2026-02-26
EP4277628A1 (en) 2023-11-22
AU2022208424A9 (en) 2024-05-09
EP4277628C0 (en) 2025-09-24
AU2022208424A1 (en) 2023-08-24
ZA202307855B (en) 2025-12-17
MX2023008016A (es) 2023-07-13
EP4277628B1 (en) 2025-09-24
KR20230133317A (ko) 2023-09-19
JP7837338B2 (ja) 2026-03-30
JP2024503372A (ja) 2024-01-25
PL4277628T3 (pl) 2026-02-09
WO2022152902A1 (en) 2022-07-21
IL304232A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
EP4277628B1 (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
Zhu et al. Hematopoietic recovery following chemotherapy is improved by BADGE-induced inhibition of adipogenesis
Gonzaga et al. Mesenchymal stem cell benefits observed in bone marrow failure and acquired aplastic anemia
ES2418433T3 (es) Modulación de receptores de catecolaminas
US20120093782A1 (en) Enhanced Hematopoietic Stem Cell Engraftment
JP2022121446A (ja) 幹細胞移植のための方法および組成物
EP4110900A1 (en) Generating aorta-gonad-mesonephros-like hematopoietic cells from human pluripotent stem cells under a defined condition
KR101400900B1 (ko) 탄시논을 유효성분으로 함유하는 자연살해세포 분화 또는 활성 증진용 조성물
US20250333462A1 (en) Periostin compounds for the treatment of haematological complications
JP7677893B2 (ja) 幹細胞機能を向上させるための薬剤及び方法
CN121343895B (zh) 二氢乳清酸脱氢酶抑制剂在制备巨核细胞或血小板中的应用
JP6339668B2 (ja) 細胞動員に使用するデキストラン硫酸
KR20200118449A (ko) 형질전환 성장 인자 베타-내성 자연 살해 세포
US9199028B2 (en) Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients
HK40100349A (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
HK40100349B (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
CN110551688B (zh) 一种诱导体细胞重编程为造血干/祖细胞且促进造血干/祖细胞体外扩增的组合物及其应用
RU2360965C1 (ru) СПОСОБ УВЕЛИЧЕНИЯ КОЛИЧЕСТВА ГЕМОПОЭТИЧЕСКИХ НЕДИФФЕРЕНЦИРОВАННЫХ СТВОЛОВЫХ КЛЕТОК ПАЦИЕНТА ex vivo
CN116887844A (zh) 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐
Li et al. Interleukin 8/KC enhances G-CSF induced hematopoietic stem/progenitor cell mobilization in Fancg deficient mice
Nguyen et al. Safety and efficacy of stem cell therapy for treatment severe traumatic brain injury
RU2454247C1 (ru) Способ профилактики острой реакции трансплантат против хозяина после трансплантации аллогенного костного мозга
KR101661199B1 (ko) 인간골수백혈병세포주로부터 분화유도된 거핵구 및 혈소판을 생산하는 방법
CN116509834A (zh) 化合物在制备造血干/祖细胞增殖和损伤修复药物中的应用
KR20260030184A (ko) 인간 제대혈 cd34+ 세포로부터 제대혈 유래 골수성 억제세포의 제조방법, 상기 제조방법에 의해 제조된 제대혈 유래 골수성 억제세포 및 이의 약제학적 용도

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250103

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250103

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251216

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260114

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260114

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260220

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260220

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260220

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260223